Medical Science Liaison (MSL) Neurology – South Central at Vor Bio

Remote

Vor Bio Logo
Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

Candidates must possess strong scientific acumen and the ability to translate complex data into meaningful discussions with external experts. Excellent relationship-building skills and comfort engaging with neurologists, researchers, and healthcare providers are essential. A demonstrated understanding of clinical trial operations and site engagement, along with familiarity with the U.S. healthcare environment across academic and community neurology practices, is required. The role also demands the ability to collaborate effectively across diverse internal functions and work independently.

Responsibilities

The Medical Science Liaison (MSL) in Neurology will serve as a scientific expert, fostering partnerships with healthcare professionals, clinical researchers, and advocacy groups in neurological disorders. Responsibilities include delivering high-quality scientific exchange, providing education on emerging data, supporting clinical trial execution, and capturing insights that inform medical strategy, with a primary focus on advancing the development of telitacicept for Myasthenia Gravis. This involves building and maintaining expertise in the company’s neurology pipeline, serving as a trusted scientific resource, identifying opportunities for scientific communication and evidence generation, and participating in neurology-focused scientific meetings. The MSL will also establish and nurture relationships with key opinion leaders, facilitate scientific exchange, engage investigators and clinical trial sites, and contribute to evidence generation through IIS and outcomes research collaborations. Additionally, the role requires close collaboration with Medical Affairs, Clinical, and Commercial teams to ensure scientific alignment and launch readiness, providing compliant responses to medical inquiries, and supporting advisory boards and educational initiatives.

Skills

Neurology
Autoimmune disease
Clinical trial execution
Scientific exchange
Medical strategy
Disease biology
Treatment landscape
Healthcare professionals
Clinical researchers
Advocacy groups

Vor Bio

Develops targeted therapies for blood cancers

About Vor Bio

Vor Biopharma focuses on developing treatments for blood cancers, particularly Acute Myeloid Leukemia (AML). Their approach is designed to protect healthy cells while specifically targeting and eliminating cancerous cells. This method aims to improve the effectiveness of blood cancer treatments. Vor Biopharma serves patients with blood cancers, their caregivers, and medical professionals in hospitals and oncology centers. What sets Vor Biopharma apart from competitors is their strong emphasis on research and development, investing significantly in scientific research to create a proprietary platform and pipeline of therapies. They generate revenue through partnerships with other pharmaceutical companies and licensing agreements, with the goal of commercializing their therapies after obtaining regulatory approval. The company's mission is to transform the treatment landscape for blood cancers by providing innovative therapies that prioritize patient safety and efficacy.

Cambridge, MassachusettsHeadquarters
2015Year Founded
$147.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Vacation
Parental Leave
401(k) Retirement Plan
401(k) Company Match
Commuter Benefits

Risks

Significant YTD price decline of -62.76% may affect investor confidence.
Key clinical trial data updates are not expected until 2025, causing uncertainty.
Increased competition from companies like Editas Medicine poses potential conflicts.

Differentiation

Vor Bio focuses on protecting healthy cells while targeting cancerous ones.
The company specializes in innovative treatments for blood cancers like AML.
Vor Bio's approach aligns with the rise of personalized medicine.

Upsides

Recent $55.6M funding supports clinical trials and extends cash runway to 2025.
FDA's acceptance of gene therapies may ease approval for Vor Bio's treatments.
Advancements in CRISPR technology enhance precision of Vor Bio's gene editing.

Land your dream remote job 3x faster with AI